This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Uldall, P. Articles by Beck, S. Search for Related Content PubMed Articles by Uldall, P. Articles by Beck, S. Social Bookmarking                         What's this?

Vigabatrin in Pediatric Epilepsy—An Open Study

Dianalund Epilepsy Hospital, Dianalund, Denmark

Jorgen Alving, MD

Dianalund Epilepsy Hospital, Dianalund, Denmark

Lennart Gram, MD, PhD

Dianalund Epilepsy Hospital, Dianalund, Denmark

Simon Beck, MB, ChB

Marion Merrell Dow Research Centre, Winnersh, UK

The antiepileptic effect of vigabatrin in adults has been demonstrated in a number of controlled studies. In children, the effect of vigabatrin has been investigated only to a limited extent. In order to assess the long-term effect and safety of vigabatrin in patients with severe epilepsy, an open, add-on, dose-ranging study was initiated. To date, 27 children with partial epilepsy, two with generalized epilepsy, two with Lennox-Gastaut syndrome, and one with nonclassifiable epilepsy have been enrolled in the trial. Fifty-four percent of patients have experienced a greater than 50% reduction in seizure frequency, and four patients have become seizure free. A significant reduction in seizures was noted across the patient population, although patients who were recorded as seizure free at 3 and 6 months did suffer some recurrence of seizures. However, when seizures recurred, they did so at much lower frequency than recorded at the start of the study. Thirteen patients (39%) reported adverse events attributable to vigabatrin; one was immediately withdrawn from the study, and six had their vigabatrin dose reduced. No physiologic effects were noted on normal growth or clinical physical examination. (J Child Neurol 1991;6(Suppl):2S38-2S44).

Journal of Child Neurology, Vol. 6, No. 2 Suppl, 2S38-2S44 (1991)
DOI: 10.1177/0883073891006002081


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				A. Lortie, C. Chiron, C. Dumas, J. P. Mumford, and O. Dulac Optimizing the Indication of Vigabatrin in Children With Refractory Epilepsy J Child Neurol, June 1, 1997; 12(4): 253 - 259. [Abstract] [PDF]